Search
Deucravacitinib
go.drugbank.com/drugs/DB16650ApprovedInvestigational[L43150] It was later approved by Health Canada in November 2022 [L44216] and by the European Medicines Agency in March 2023.[L45788] … [A246943] Deucravacitinib was first approved by the FDA in September 2022 to treat moderate-to-severe plaque psoriasis.
Products: SOTYKTU® 6MG TABLETAS RECUBIERTAS, SOTYKTU 6 mg film coated tabletsEverolimus
go.drugbank.com/drugs/DB01590ApprovedInvestigationalIt is currently used as an immunosuppressant to prevent rejection of organ transplants. … In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
Products: EVEROLIMUS EG, Afinitor 3mg Dispersible TabletLisinopril
go.drugbank.com/drugs/DB00722ApprovedInvestigational[A184781,A184808,A184817] ACEIs are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. … [A184853] It functions by inhibition of angiotensin converting enzyme as well as the renin angiotensin aldosterone system.
Mixtures: LISAM 10 mg/5 mg Tabletten, LisAm 20 mg/5 mg TablettenCategories: Agents Acting on the Renin-Angiotensin System, Compounds used in a research, industrial, or household settingLercanidipine
go.drugbank.com/drugs/DB00528ApprovedInvestigationalWithdrawnIt is sold under various commercial names including Zanidip.
Mixtures: ZANITEK 10 MG/10MG FILM TABLET,90 ADET, ZANITEK 10 MG/10MG FILM TABLET, 30 ADETProducts: LERCANIDIPINA EG, CARMEN 10MGMethylprednisolone
go.drugbank.com/drugs/DB00959ApprovedInvestigationalVet approved[A188811] It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. … [L10785] In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression.
Mixtures: Physicians EZ Use M-pred, Physicians EZ Use M-predCategories: Compounds used in a research, industrial, or household settingLoratadine
go.drugbank.com/drugs/DB00455ApprovedInvestigational[A176435] A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
Mixtures: LORATADINA 5MG/FENILEFRINA 15MG TABLETAS, LARITOL EXProducts: LORATADINA EG, SAFETIN FTAcylcarnitine (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine
smpdb.ca/view/SMP0123485Metabolic-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoylcarnitine. … inner membrane to once again form (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3-oxocyclopentyl]hept-5-enoyl-CoA and L-carnitine. (5Z)-7-[(1R,2E,5S)-5-hydroxy-2-[(2E)-oct-2-en-1-ylidene]-3
Drugs: Biotin · Adenosine phosphate · ATP · Levocarnitine · Magnesium cation · Pyrophosphoric acid +1 moreValproic acid
go.drugbank.com/drugs/DB00313ApprovedInvestigational[A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. … It first received approval on February 28, 1978 from the FDA under the trade name Depakene.[L6190] Since then, it has been investigated for neuroprotective, anti-manic, and anti-migraine effects.
Mixtures: Depakine Chronosphere 50 mg Retardgranulat in Beuteln, Depakine Chronosphere 50 mg Retardgranulat in BeutelnSynonyms: 2-n-propyl-n-valeric acid, n-DPAPenciclovir
go.drugbank.com/drugs/DB00299ApprovedPenciclovir is a synthetic acyclic guanine derivative with antiviral activity used for the treatment of various herpes simplex virus (HSV) infections. Displaying low toxicity and good selectivity, penciclovir is a nucleoside analogue.
Products: EX-LOVIR % 1 KREM 2 G, Fenivir - Fieberblasencreme 10mg/g CremePanobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. … Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma.
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Products: FARYDAK HARD GELATIN CAPSULE 10mg, FARYDAK HARD GELATIN CAPSULE 15mg